Multiplex PCR allows for rapid analysis of the human microbiota. This approach opens up a new era for diagnosis and treatment of chronic diseases, and for the development of personalised nutraceuticals.

In small hospitals, the lack of advanced laboratories leads to significant diagnostic delays. Decentralised molecular diagnostics, based on portable and connected PCR systems, is revolutionising this scenario. The article examines how point-of-care testing allows even peripheral facilities to perform rapid genetic analysis on site, reducing reporting times from days to minutes. The clinical and economic benefits are highlighted. The technological solutions adopted to ensure quality and ease of use and the integrated network model with centralised laboratories are discussed.

The molecular diagnostics market is shifting from large laboratories to distributed and point-of-care solutions. Significant growth is expected between 2024 and 2030, driven by portable PCR, multiplex testing and cloud/AI integration. Ulisse Biomed, with its Hyris System™ platform (bCUBE™, bAPP™, ambient-stable reagents), is positioning itself as an end-to-end player capable of scaling this revolution.

The convergence of PCR and artificial intelligence in the Ulisse Biomed ecosystem enables standardised interpretation of Ct curves, real-time quality control and centralised governance of distributed networks. The result is a faster, more reliable and scalable diagnostic cycle.

Personalised medicine replaces the “one-size-fits-all” model with tailored treatments based on genetic and molecular profiles. The article shows how multiplex diagnostics—decentralised, modular and integrable—enable faster and more sustainable treatment pathways, with Ulisse Biomed as the infrastructure enabler.

Modular qPCR testing quantifies Akkermansia, Faecalibacterium, Lactobacillus and Bifidobacterium within hours, enabling customised pathways and Diagnostics as a Service models.

Decentralised molecular diagnostics are revolutionising the rapid identification of respiratory infections. Thanks to portable multiplex real-time PCR systems, it is now possible to obtain accurate diagnoses of influenza, RSV, SARS-CoV-2 and other diseases on-site, optimising reporting times and supporting timely clinical decisions.

Core Lab or Point-of-Care? True innovation is in the synergy. A reasoned comparison of two complementary architectures of modern diagnostics.

The Hyris System™ ecosystem from Ulisse Biomed combines portable hardware, cloud software and advanced reagents in a modular and scalable platform.

The future of diagnostics is cloud-based. CDA revolutionises laboratory workflows and creates strategic value from every data point.

Innovation only has value if it is also sustainable. Ulisse Biomed makes this a guiding principle, combining AI, cloud technology and decentralisation.

The microbiota is an invisible ecosystem that is crucial to our health. This article explores its fundamentals, functions and diagnostic value.

What lies behind innovation at Ulisse Biomed? Three interviews reveal the method, vision and culture of R&D.

The artificial intelligence embedded in the Hyris™ system is transforming PCR into a predictive and distributed platform.

Decentralised diagnostics is growing in double figures, driven by portable PCR, DaaS and AI models. That is why it is the trend to watch by 2030.

PCR is the technique that revolutionised molecular diagnostics. This article explains the basics in a clear and professional manner.

A new editorial section to read the future of molecular diagnostics through vision, method and authoritative content.